CHP
VYGR icon

Cable Hill Partners’s Voyager Therapeutics VYGR Stock Holding History

Cable Hill Partners’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-250
Closed -$5K – 886
2018
Q2 		$5K Sell
250
-750
-75% -$14.8K ﹤0.01% 684
2018
Q1 		$17K Buy
1,000
+700
+233% +$15.1K 0.01% 385
2017
Q4 		$5K Buy
+300
New +$5.14K ﹤0.01% 747

Other funds holding VYGR

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return

Cable Hill Partners's VYGR Position: Q3 2018 in Review

Cable Hill Partners sold out of Voyager Therapeutics (VYGR) in Q3 2018, closing a stake of 250 shares — an estimated $5K sold.

Cable Hill Partners first reported a position in VYGR in Q4 2017 and held it in 3 quarters. The position peaked at $17K in Q1 2018. 119 funds tracked by Wall St. Rank hold VYGR as of Q3 2018.

  • Cable Hill Partners reported no remaining Voyager Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Cable Hill Partners sold 250 Voyager Therapeutics shares in Q3 2018, an estimated $5K.
  • Cable Hill Partners first reported a position in Voyager Therapeutics in Q4 2017 and held it in 3 quarters.
  • Cable Hill Partners's Voyager Therapeutics position peaked at $17K in Q1 2018.
  • 119 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q3 2018.

Based on Cable Hill Partners's 13F filing for Q3 2018, filed 14 Nov 2018.